SLC6A11 and colitis: These findings collectively underscore the role of (R)-2,3-dihydroxy-isovalerate in mediating the therapeutic effects of silibinin-modulated gut microbiota on DSS-induced colitis, specifically through the GAT-3/RARβ/RORγt signaling axis.